Translate Bio to Participate in Upcoming Investor Conferences
November 01, 2018 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference
October 18, 2018 07:30 ET
|
Translate Bio, Inc.
-- Findings support ongoing Phase 1/2 study of once-weekly nebulized MRT5005 in adults with cystic fibrosis -- LEXINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq:...
Translate Bio to Participate in the Leerink Partners Roundtable Series: Rare Disease & Oncology
September 25, 2018 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Participate in Citi’s 13th Annual Biotech Conference
August 30, 2018 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Second Quarter 2018 Financial Results and Highlights Recent Development and Corporate Achievements
August 09, 2018 16:17 ET
|
Translate Bio, Inc.
-- Initiated Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis ---- Established strategic mRNA vaccines partnership with Sanofi Pasteur ---- Completed initial public offering...
Translate Bio Announces Closing of Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for Infectious Diseases
July 09, 2018 07:00 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...